Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amag Pharmaceuticals (AMAG) and Neurocrine (NBIX).
Amag Pharmaceuticals (AMAG)
Cantor Fitzgerald analyst Matthew Lillis reiterated a Hold rating on Amag Pharmaceuticals today and set a price target of $18. The company’s shares closed yesterday at $16.13.
Lillis wrote:
“: We reiterate our Neutral rating and $18 price target on AMAG. We believe the company’s ability to demonstrate that existing and pipeline assets can adequately replace lost top-line growth due to Makena generic competition is key to the stock’s performance over the next 12-18 months. We believe future expectations for Vyleesi (for hypoactive sexual desire disorder (HSDD) in women) will have the greatest share impact, with AMAG-423 (for severe preeclampsia) and ciraparantag (anticoagulant reversal agent) looking toward potential launches in 2022. We think investors are also focused on Makena autoinjector (A.I.) for near- term growth, which has decelerated, in our view.”
According to TipRanks.com, Lillis is a 2-star analyst with an average return of 0.6% and a 50.0% success rate. Lillis covers the Healthcare sector, focusing on stocks such as Taiwan Liposome Company Ltd, Supernus Pharmaceuticals, and Evofem Biosciences Inc.
Amag Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $19.50.
See today’s analyst top recommended stocks >>
Neurocrine (NBIX)
Cantor Fitzgerald analyst Charles Duncan reiterated a Buy rating on Neurocrine today and set a price target of $127. The company’s shares closed yesterday at $87.78.
Duncan noted:
“. We reiterate our Overweight rating and raise our PT to $127 from $121 for NBIX. On Tuesday, Neurocrine reported 4Q18 revenues of $131.5M ($130M Ingrezza revs, pre-announced in Jan.) and cash of ~$867M, more than sufficient to fund pipeline and commercial effort into ’21. Although we expect Qt’ly growth to vary with the donut hole impact and seasonal variations, we remain convinced that Ingrezza sales will continue to grow in 2019 (in part due to the recent investments in the sales force and DTC campaign) and beyond. We also anticipate, but limit our valuation perspective from, the pipeline kicking in to contribute with (first at bat) an opicapone NDA filing this year and approval in ’20 for this potentially best-in-class and therapeutic paradigm-shifter, Parkinson’s candidate.”
According to TipRanks.com, Duncan is a 3-star analyst with an average return of 1.0% and a 47.1% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, KalVista Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
Currently, the analyst consensus on Neurocrine is a Strong Buy with an average price target of $103.92, which is a 18.4% upside from current levels. In a report issued on January 29, Oppenheimer also assigned a Buy rating to the stock with a $105 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NBIX:
